Department of Medicine, Krantz Family Center for Cancer Research, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Curr Opin Immunol. 2024 Dec;91:102504. doi: 10.1016/j.coi.2024.102504. Epub 2024 Nov 14.
The presence of B cells and their subtypes in the tumor environment has been recognized a for very long time. Immunoglobulins specific for more than thousands of tumor-associated antigens were detected in the sera of patients with cancer; however, antibody-mediated cancer cell killing is usually impaired. The role of humoral immune response remained elusive until recently, with new discoveries regarding their contribution in regulating antitumor immunity, particularly during immunotherapy. Humoral immunity has been described to promote or attenuate tumorigenesis and can have opposing effects on therapeutic outcome in different tumor entities. The antagonism effect of B cells depends on their subtypes and immunoglobulin isotypes and is regulated by their spatial distribution and localization. In this short review, we will focus on how the spatial organization of B cells within the tumor microenvironment, tumor-associated lymph nodes, and tertiary lymphoid structures define their fate and function and contribute to the regulation of antitumor immunity.
很长一段时间以来，人们一直认识到 B 细胞及其亚型存在于肿瘤环境中。在癌症患者的血清中检测到针对超过数千种肿瘤相关抗原的特异性免疫球蛋白；然而，抗体介导的癌细胞杀伤通常受损。直到最近，人们才发现体液免疫反应的作用，特别是在免疫治疗中，它在调节抗肿瘤免疫方面的作用。体液免疫被描述为促进或抑制肿瘤发生，并且在不同的肿瘤实体中对治疗结果有相反的影响。B 细胞的拮抗作用取决于它们的亚型和免疫球蛋白同种型，并且受它们的空间分布和定位调节。在这篇简短的综述中，我们将重点讨论 B 细胞在肿瘤微环境、肿瘤相关淋巴结和三级淋巴结构中的空间组织如何决定它们的命运和功能，并有助于调节抗肿瘤免疫。
